Actively Recruiting
Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters
Led by Cardiocentro Ticino · Updated on 2026-03-19
58
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow. The FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps. These features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure. Our study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival
CONDITIONS
Official Title
Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed atrial fibrillation (AF) confirmed by ECG, Holter monitor, or implantable cardiac device
- Candidate for ablation according to current atrial fibrillation guidelines
- Age 18 years or older at time of informed consent
- Signed informed consent obtained
You will not qualify if you...
- Previous left atrial ablation or left atrial surgery
- Presence of intracardiac thrombus
- Persistent atrial fibrillation lasting more than 3 years
- Severe mitral regurgitation or moderate-to-severe mitral stenosis
- Pregnancy (all women under 50 years undergo an HCG blood test to exclude pregnancy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cardiocentro Ticino - Ente Ospedaliero Cantonale
Lugano, Canton Ticino, Switzerland, 6900
Actively Recruiting
Research Team
M
Marco Bergonti, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here